2005

WHOOPING CRANE TITERS TO EASTERN EQUINE ENCEPHALITIS VACCINATIONS

Glenn H. Olsen
USGS Patuxent Wildlife Research Center

Erin Kolski
Eleanor Roosevelt High School

Jeff S. Hatfield
USGS Patuxent Wildlife Research Center, jhatfield@usgs.gov

Douglas E. Docherty
USGS National Wildlife Health Center

Follow this and additional works at: [https://digitalcommons.unl.edu/nacwgproc](https://digitalcommons.unl.edu/nacwgproc)

Part of the Behavior and Ethology Commons, Biodiversity Commons, Ornithology Commons, Population Biology Commons, and the Terrestrial and Aquatic Ecology Commons

https://digitalcommons.unl.edu/nacwgproc/41

This Article is brought to you for free and open access by the North American Crane Working Group at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in North American Crane Workshop Proceedings by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Eastern Equine Encephalitis (EEE) is a clinically important disease of horses, people, and some birds including whooping cranes (*Grus americana*). EEE is classified as a zoonotic vector-borne alpha virus. The virus is found in eastern North America and is maintained and amplified by a mosquito-wild bird cycle. Native wild passerines carry the virus and initiate the cycle, with viremic birds being found 37-51 days before virus is first detected in mosquitoes beginning in July or August and lasting through October (Crans et al. 1994). The virus is then spread by the mosquitoes and amplified in the hatch-year passerines. EEE does not typically produce morbidity or mortality in native passerines, but has been known to cause mortality in non-native birds (pheasants, emus; Tengelsen 2001), horses, bats (Main 1979), and humans.

Vaccination as a tool to control arbovirus infections in horses is a widespread practice that provides effective protection (American Association of Equine Practitioners, 1995; Tengelsen et al. 2001). Commercially available equine vaccines for EEE are used to protect emus from the disease (Tengelson et al. 2001). Between September 17 and December 17, 1984 an epizootic of EEE killed 7 of 39 captive whooping cranes at the Patuxent Wildlife Research Center, Laurel, Maryland USA (Dein et al. 1986, Carpenter et al. 1989). Following the 1984 EEE epizootic at Patuxent, all whooping cranes began receiving annual injections of EEE vaccine (Clark et al. 1987; Olsen et al. 1997). There were no challenge studies done with the endangered whooping cranes. Naturally occurring epizootics were documented in sentinel birds and in mosquitoes, with no morbidity or mortality in captive whooping cranes. This led to the conclusion that the vaccination program was efficacious (Olsen et al. 1997). In 2000 and 2001, the human EEE vaccine previously used was not available for the whooping cranes at Patuxent. As an alternative; the birds were vaccinated with a commercially available equine vaccine.

The objective of this study was to compare antibody titer levels observed in years when the human vaccine was used with the 2 years when the equine vaccine was used. When an equine vaccine was first tested in the 1980’s, the titer levels were lower than those seen with the human vaccine (Clark et al. 1987), and we wanted to discover if this was still true with the currently available equine vaccine.

**METHODS**

All adult whooping cranes housed at Patuxent were kept in 15 x 20 m outdoor pens. Very young whooping crane chicks being costume-reared for release programs spent the first 7-10 days confined indoors in 3 x 3 m pens, but afterwards were in indoor/outdoor pens until 40-50 days of age, after which time they were housed totally outside. All whooping crane chicks received their first injection of EEE vaccine in July. For 1989-1999 this was 0.5 ml intramuscular injection of the PE 6 WRAIR strain human EEE vaccine (The Salk Institute, Government Service Division, Swiftwater, Pennsylvania, USA). This was followed 1 month later by an intramuscular injection of 1.0 ml. Yearly revaccination using the same 1.0 ml dose of the PE 6 WRAIR EEE vaccine occurred in late August or early September, to coincide with the seasonal peak of activity (August-October) for the EEE carrying mosquito (*Culiseta melanura*) at Patuxent (Pagac et al, 1992).

In 2000 and 2001, all adult whooping cranes received a 1.0 ml intramuscular dose of Encephaloid M (EEE and western equine encephalitis vaccine, Fort Dodge Laboratories, Fort Dodge, Iowa USA) in August of each year. All whooping crane chicks received the same Encephaloid M as 0.5 ml intramuscularly in July and 1.0 ml intramuscularly in August of their hatch year.

Blood samples to obtain serum for titers were collected...
in late October or early November of each year during routine health examinations of the whooping cranes. Serum was shipped frozen to the USGS National Wildlife Health Center, Madison, Wisconsin, USA for analysis by hemaglutination-inhibition testing (HI, 1994-1997) or by serum neutralization testing (SN, 2000-2001) at the National Veterinary Services Laboratory, Ames, Iowa, USA. We analyzed the EEE titers for 1994, 1996 and 1997, years in which the human vaccine was used, and the most recent years (2000, 2001) when the equine vaccine was used. Due to budget constraints, no titers had been tested in 1995, 1998 or 1999.

Data were analyzed with a repeated measure analysis of variance (ANOVA) using a compound symmetry model in the mixed-models procedure of SAS (Statistical Analysis System, Version 6.12; 1997). The subject factor was crane identification number nested with gender. Prior to analysis, titers were transformed with a log 10 transformation to help achieve normality and homoscedasticity of residuals. Pairwise comparisons were performed on the least square means using a Tukey multiple comparison procedure (P < 0.05).

RESULTS AND DISCUSSION

Antibody titers were available from a total of 52 whooping cranes for the years 1994-1997 (human vaccine) and 2000-2001 (equine vaccine). For the 3 years when the human vaccine was used, the titers were highly variable (Table 1). The titers for 1994 were very low, while the 1996 titers were high, equivalent to those found with the equine vaccine. The 1997 titers were higher than 1994 but lower than 1996. Table 1 shows the untransformed means, sample sizes, and standard deviations, as well as pairwise comparison results of the log-transformed least square means. The mean titers for 1996, 2000, and 2001 were not significantly different (P > 0.05) from each other. The titer means for 1994 and 1997 were significantly different from each other and were different from 1996, 2000, 2001 EEE mean titers (P < 0.05). We used two different tests to determine the titers (HI and SN) but saw no differences in titer levels in 1996 (HI), 2000 or 2001 (SN). Titters seen with the human vaccine were considered protective due to the absence of morbidity or mortality seen in whooping cranes in years since 1984 when EEE was detected in mosquitoes and sentinel birds (Olsen et al. 1997). The equine vaccine tested produced titers equal to or higher than those produced by the human vaccine, which would suggest adequate protection.

Initial testing of a commercially available equine EEE vaccine and the Salk human EEE vaccine in the 1980’s had shown superior titer levels when using the human vaccine (Clark et al, 1987). Therefore, the decision was made to vaccinate the captive whooping cranes with the human vaccine. Unavailability of this vaccine starting in 2000 prompted the switch to an equine form of EEE vaccine. These results show that the titers obtained from this new equine EEE vaccine equal or exceed the titers seen with the human EEE vaccine used in the past. The human vaccine continues to be unavailable today, and, given current world events, it is unlikely to be released by the military any time soon. Therefore, continued use of an equine EEE vaccine appears to be an appropriate management tool to prevent this disease in captive whooping cranes.

ACKNOWLEDGMENTS

The authors thank the Crane Crew at the Patuxent Wildlife Research Refuge Center for their help in obtaining blood samples, veterinary technicians Lorie Shaul, Alex Lewis and Jennifer Kodak at Patuxent, the laboratory technicians at the

<table>
<thead>
<tr>
<th>Year</th>
<th>Sample Size (n)</th>
<th>Geometric Mean</th>
<th>Standard Error</th>
<th>Tukey’s test&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>33</td>
<td>6.08</td>
<td>1.22</td>
<td>A</td>
</tr>
<tr>
<td>1996</td>
<td>39</td>
<td>88.13</td>
<td>1.21</td>
<td>B</td>
</tr>
<tr>
<td>1997</td>
<td>37</td>
<td>15.07</td>
<td>1.21</td>
<td>C</td>
</tr>
<tr>
<td>2000</td>
<td>52</td>
<td>81.23</td>
<td>1.19</td>
<td>B</td>
</tr>
<tr>
<td>2001</td>
<td>51</td>
<td>82.64</td>
<td>1.19</td>
<td>B</td>
</tr>
</tbody>
</table>

<sup>a</sup> Means with the same letter are not significantly different (P > 0.05), based on Tukey’s multiple comparison procedure of the least square means generated from the log-transformed titer levels in the repeated measures ANOVA.
NWHC, especially Renee Long and Kristina Egstad. We also thank the USAMRIID, Fort Detrick, Fredrick Maryland, USA for supplying us with the SALK human EEE vaccine used at Patuxent for the protection of the whooping cranes throughout the 1990’s.

LITERATURE CITED


